Abd El-Rehim DM et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004;203(2):661-71. Abstract

Albain K et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: Mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG- 8814). San Antonio Breast Cancer Symposium 2004;Abstract 37.

Anderson GL et al; Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women’s Health Initiative randomized controlled trial. JAMA 2004;291(14):1701-12. Abstract

Birnbaum D et al. Basal and luminal breast cancers: Basic or luminous? (review). Int J Oncol 2004;25(2):249-58. Abstract

Braithwaite RS et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003;18(11):937-47. Abstract

Brufsky A et al. Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant Letrozole (Let): 12 mos BMD results of the Z-FAST trial. Proc ASCO 2005;Abstract 533.

Chang HY et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005;102(10):3738-43. Abstract

Chlebowski RT. Bone health in women with early-stage breast cancer. Clin Breast Cancer 2005;5(Suppl 2):35-40. Abstract

Coombes RC et al; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081-92. Abstract

Fisher B et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: Long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004;364(9437):858-68. Abstract

Gnant M et al. Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (± zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: Results of a randomized multicenter trial. San Antonio Breast Cancer Symposium 2002;Abstract 12.

Gnant M et al. Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen — Bone density subprotocol results of a randomized multicenter trial (ABCSG-12). San Antonio Breast Cancer Symposium 2004;Abstract 6.

Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract

Hillner BE et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21(21):4042- 57. Abstract

Howell A et al, on behalf of the ATAC Trialists’ Group. Effect of anastrozole on bone mineral density: 2-year results of the arimidex (anastrozole), tamoxifen, alone or in combination (ATAC) trial. San Antonio Breast Cancer Symposium 2003;Abstract 129.

Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Jackson J et al. Safety issues surrounding the use of aromatase inhibitors in breast cancer. Expert Opin Drug Saf 2003;2(1):73-86. Abstract

Jakesz R et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results from 3,224 women enrolled in the ABCSG Trial 8 and the ARNO 95 trial. Presentation. San Antonio Breast Cancer Symposium 2004;Abstract 2.

Jakesz R et al. Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). Proc ASCO 2005;Abstract 527.

Locker GY et al. The time course of bone fractures observed in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial. Proc ASCO 2003;Abstract 98.

Paik S et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004a;351(27):2817-26. Abstract

Paik S et al. Expression of the 21 genes in the Recurrence Score assay and prediction of clinical benefit from tamoxifen in NSABP study B-14 and chemotherapy in NSABP study B-20. San Antonio Breast Cancer Symposium 2004b;Abstract 24.

Perou CM et al. Molecular portraits of human breast tumours. Nature 2000;406(6797):747-52. Abstract

Sorlie T et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100(14):8418-23. Abstract

Thürlimann BJ et al. BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor positive breast cancer. Presentation. ASCO 2005;Abstract 511.

Troester MA et al. Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res 2004;64(12):4218-26. Abstract

Winer EP et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptorpositive breast cancer: Status report 2004. J Clin Oncol 2005;23(3):619-29. Abstract